Core Viewpoint - The company reported a loss of RMB 23.4 billion for 2025, primarily due to non-cash impairment charges related to past projects and goodwill from non-core business segments, rather than a deterioration in operational fundamentals [1] Financial Performance - The loss of RMB 23.4 billion is attributed to non-cash losses, which will not impact the company's daily operations, cash flow, or business operations [1] - The core businesses, including pharmaceuticals and insurance, continue to show stable growth despite the reported loss [1] Strategic Focus - The board's decision to undertake asset impairment is aimed at allowing the company to better concentrate resources and efforts on high-growth core sectors [1]